July 22, 2024

FDA Makes Alzheimer’s Drug Leqembi Widely Accessible

The F.D.A. gave full approval to the drug, but added a black-box warning about safety risks. Medicare said it would cover most of the high cost.The F.D.A. gave full approval to the drug, but added a black-box warning about safety risks. Medicare said it would cover most of the high cost.Read MoreFood and Drug Administration, Drugs (Pharmaceuticals), Alzheimer’s Disease, Medicare, Clinical Trials, Biogen Inc, Eisai Co Ltd, United States, Aduhelm (Drug), Leqembi (Drug)NYT > Health

Leave a Reply

Your email address will not be published. Required fields are marked *